Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | UBE2M | P61081 | 5/20 | 0.50 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13167708 | 0.87 | LMNA (0.46) | CHRM2CHRM3OPRM1UBE2MDCUN1D1 | |
| SCHEMBL4131135 | 0.86 | OPRM1 (0.39) | CHRM2CHRM3OPRM1UBE2MDCUN1D1 | |
| SCHEMBL909709 | 0.81 | UBE2M (0.40) | UBE2MDCUN1D1LMNA | |
| SCHEMBL3329038 | 0.80 | LNPEP (0.37) | UBE2MDCUN1D1LMNA | |
| SCHEMBL2767755 | 0.80 | KDM4E (0.37) | DCUN1D1ALDH1A1 | |
| SCHEMBL5040313 | 0.79 | DCUN1D1 (0.38) | UBE2MDCUN1D1PKM | |
| Water SCHEMBL3517045 | 0.79 | KDM4E (0.37) | DCUN1D1ALDH1A1 | |
| SCHEMBL13167704 | 0.78 | KCNH2 (0.60) | ACHEBCHE | |
| Hydrochloric Acid SCHEMBL3517676 | 0.77 | KCNH2 (0.59) | ACHEBCHE | |
| SCHEMBL4135802 | 0.77 | KCNH2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2221309-B1 | NAPHTHYRIDINE DERIVATIVE MONOHYDRATE AND METHOD FOR PRODUCING THE SAME | TOYAMA CHEMICAL CO LTD (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8354426-B2 | Naphthyridine derivative monohydrate and method for producing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20100249417-A1 | NOVEL NAPHTHYRIDINE DERIVATIVE MONOHYDRATE AND METHOD FOR PRODUCING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2221309-A1 | NOVEL NAPHTHYRIDINE DERIVATIVE MONOHYDRATE AND METHOD FOR PRODUCING THE SAME | Toyama Chemical Co., Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249417-A1 | NOVEL NAPHTHYRIDINE DERIVATIVE MONOHYDRATE AND METHOD FOR PRODUCING THE SAME | QDPR, NDC1, NRDC | CHRM2 3018/4885CHRM3 2592/4885OPRM1 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.